These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8897518)
1. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Talve L; Kainu J; Collan Y; Ekfors T Pathol Res Pract; 1996 Aug; 192(8):825-33. PubMed ID: 8897518 [TBL] [Abstract][Full Text] [Related]
2. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. Talve LA; Collan YU; Ekfors TO J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921 [TBL] [Abstract][Full Text] [Related]
3. Correlation of nuclear morphometry of primary melanoma of the skin with clinicopathological parameters and expression of tumor suppressor proteins (p53 and p16(INK4a)) and bcl-2 oncoprotein. Mijovic Z; Kostov M; Mihailovic D; Zivkovic N; Stojanovic M; Zdravkovic M J BUON; 2013; 18(2):471-6. PubMed ID: 23818364 [TBL] [Abstract][Full Text] [Related]
4. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin. Karbowniczek M; Chosia M; Domagała W Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263 [TBL] [Abstract][Full Text] [Related]
5. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Wang Y; Dai DL; Martinka M; Li G Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537 [TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A; J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783 [TBL] [Abstract][Full Text] [Related]
8. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007 [TBL] [Abstract][Full Text] [Related]
9. PUMA expression is significantly reduced in human cutaneous melanomas. Karst AM; Dai DL; Martinka M; Li G Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057 [TBL] [Abstract][Full Text] [Related]
10. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887 [TBL] [Abstract][Full Text] [Related]
11. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901 [TBL] [Abstract][Full Text] [Related]
12. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions. Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642 [TBL] [Abstract][Full Text] [Related]
13. Use of oncogene expression as an independent prognostic marker for primary melanoma. Grover R; Pacifico MD; Wilson GD; Sanders R Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057 [TBL] [Abstract][Full Text] [Related]
14. [Expression of P53 protein in cutaneous melanoma]. Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650 [TBL] [Abstract][Full Text] [Related]
15. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas. Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475 [TBL] [Abstract][Full Text] [Related]
16. Novel role for RGS1 in melanoma progression. Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492 [TBL] [Abstract][Full Text] [Related]
17. p53 Protein expression in nevi and melanomas. Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076 [TBL] [Abstract][Full Text] [Related]
18. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497 [TBL] [Abstract][Full Text] [Related]
19. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Väisänen A; Kuvaja P; Kallioinen M; Turpeenniemi-Hujanen T Hum Pathol; 2011 Aug; 42(8):1103-11. PubMed ID: 21334717 [TBL] [Abstract][Full Text] [Related]
20. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]